A Phase 3 interventional study of Lisdexamfetamine Dimesylate (LDX) and Methylphenidate Hydrochloride in ADHD, sponsored by Shire. Completed at 49 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 5th largest by enrollment, is one of 9 that started in 2008, is one of 15 in phase 3, and was the 16th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 8 yrs–198 mo
By country, each count listing its studies:
lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 23
First in 2004; this study’s year is marked. 9 started in 2008.
This study's enrollment of 336 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 48 across the 51 interventional studies. Of the 49 that completed or were terminated, 37 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
57 studies in Attention Deficit Disorder with Hyperactivity by Takeda: none open now, none under way, none of them phase 3. Of 55 finished, 37 (67%) have results posted.
Among the 57 studies in Attention Deficit Disorder with Hyperactivity by Takeda, this one is the 13th largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2008, is one of 32 in phase 3, and was the 26th registered.
Takeda’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 57 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overencapsulated LDX 30, 50, or 70mg
Drug: Lisdexamfetamine Dimesylate (LDX)
Overencapsulated Concerta 18, 36, or 54mg
Drug: Methylphenidate Hydrochloride
Overencapsulated Placebo
Drug: Placebo
30, 50 or 70mg capsule once per day (Overencapsulated)
Also known as: Vyvanse™
18, 36, or 54mg tablet one per day (Overencapsulated)
Also known as: Concerta®, OROS MPH
Placebo capsule once per day (Overencapsulated)
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.
Time frame: Baseline and up to 7 weeks
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: Up to 7 weeks
Change From Baseline in Conner's Parent Rating Scale - Revised (CPRS-R) Total Score at up to 7 Weeks
The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.
Time frame: Baseline and up to 7 weeks
Health Utilities Index-2 (HUI-2) Scores at up to 7 Weeks
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
Time frame: Baseline and up to 7 weeks
Change From Baseline in the Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at up to 7 Weeks
The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.
Time frame: Baseline and up to 7 weeks
Change From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
Time frame: Baseline and up to 7 weeks
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at up to 7 Weeks
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.
Time frame: Baseline and up to 7 weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a 19-item semi-structured interview designed to capture suicide-related thoughts and behaviors.
Time frame: Up to 7 weeks
| Milestone | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Started | 113 | 112 | 111 |
| Completed | 80 | 74 | 42 |
| Not completed | 33 | 38 | 69 |
| Withdrew: Adverse event | 5 | 2 | 4 |
| Withdrew: Protocol violation | 3 | 3 | 2 |
| Withdrew: Withdrawal by subject | 4 | 5 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 11 | 22 | 54 |
| Withdrew: Unable to swallow capsule | 2 | 1 | 1 |
| Withdrew: Personal reason | 3 | 0 | 0 |
| Withdrew: Exclusion criteria met | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 0 |
| Withdrew: Due to holiday season | 2 | 0 | 1 |
| Withdrew: Randomization error | 0 | 0 | 1 |
| Withdrew: Medical monitor decision | 0 | 0 | 1 |
| Withdrew: Moved to another country | 0 | 1 | 0 |
| Withdrew: Subject wanted dose reduction | 0 | 1 | 0 |
| Withdrew: Lack of availability | 0 | 1 | 0 |
| Withdrew: Performed final visit on phone | 0 | 1 | 0 |
| Withdrew: Participation in 489-326 required | 1 | 0 | 0 |
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks | -24.3 ± 1.16 | -18.7 ± 1.14 | -5.7 ± 1.13 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| percentage of participants | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | 78.0 | 60.6 | 14.4 |
The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Change From Baseline in Conner's Parent Rating Scale - Revised (CPRS-R) Total Score at up to 7 Weeks | -24.5 ± 1.70 | -18.4 ± 1.69 | -3.2 ± 1.69 |
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Baseline | 0.811 ± 0.1451 | 0.822 ± 0.1377 | 0.806 ± 0.1460 |
| Up to 7 weeks | 0.878 ± 0.1322 | 0.887 ± 0.1151 | 0.843 ± 0.1431 |
The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.
| T-scores | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Change From Baseline in the Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at up to 7 Weeks | 8.6 ± 1.08 | 7.1 ± 1.10 | -0.2 ± 1.07 |
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Change From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks | -0.3 ± 0.04 | -0.3 ± 0.04 | 0.0 ± 0.04 |
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at up to 7 Weeks | -9.15 ± 11.264 | -9.71 ± 6.936 | -2.59 ± 7.436 |
C-SSRS is a 19-item semi-structured interview designed to capture suicide-related thoughts and behaviors.
| participants | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Suicidal ideation | 1 | 0 | 0 |
| Non-suicidal self injurious behavior | 1 | 0 | 0 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisdexamfetamine Dimesylate (LDX) | — | 3/111 (2.7%) | 80/111 (72.1%) |
| Methylphenidate Hydrochloride | — | 2/111 (1.8%) | 72/111 (64.9%) |
| Placebo | — | 3/110 (2.7%) | 63/110 (57.3%) |
| Event | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Loss of conciousnessNervous system disorders | 0/111 | 0/111 | 1/110 |
| HematomaVascular disorders | 0/111 | 0/111 | 1/110 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/111 | 0/111 | 1/110 |
| SyncopeNervous system disorders | 1/111 | 1/111 | 0/110 |
| Gastroesophageal reflux diseaseGastrointestinal disorders | 1/111 | 0/111 | 0/110 |
| AppendicitisInfections and infestations | 1/111 | 0/111 | 0/110 |
| OverdoseInjury, poisoning and procedural complications | 0/111 | 1/111 | 0/110 |
| Event | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 28/111 | 17/111 | 3/110 |
| HeadacheNervous system disorders | 16/111 | 22/111 | 22/110 |
| InsomniaPsychiatric disorders | 16/111 | 9/111 | 0/110 |
| Weight decreasedInvestigations | 15/111 | 5/111 | 0/110 |
| NasopharyngitisInfections and infestations | 8/111 | 14/111 | 8/110 |
| NauseaGastrointestinal disorders | 12/111 | 8/111 | 3/110 |
| AnorexiaMetabolism and nutrition disorders | 12/111 | 6/111 | 2/110 |
| Abdominal upper painGastrointestinal disorders | 8/111 | 9/111 | 6/110 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/111 | 8/111 | 0/110 |
| Initial insomniaPsychiatric disorders | 3/111 | 7/111 | 1/110 |
| Age, Continuous(years) | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo | Total |
|---|---|---|---|---|
| Mean | 10.9 ± 2.87 | 10.9 ± 2.63 | 11.0 ± 2.82 | 10.9 ± 2.77 |
| Age, Customized(Participants) | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo | Total |
|---|---|---|---|---|
| 6-12 years | 77 | 80 | 79 | 236 |
| 13-17 years | 34 | 31 | 31 | 96 |
| Sex: Female, Male(Participants) | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo | Total |
|---|---|---|---|---|
| Female | 24 | 21 | 19 | 64 |
| Male | 87 | 90 | 91 | 268 |
| Region of Enrollment(Participants) | Lisdexamfetamine Dimesylate (LDX) | Methylphenidate Hydrochloride | Placebo | Total |
|---|---|---|---|---|
| France | 10 | 9 | 11 | 30 |
| Hungary | 11 | 10 | 11 | 32 |
| Spain | 13 | 14 | 14 | 41 |
| Poland | 3 | 4 | 3 | 10 |
| Belgium | 4 | 3 | 4 | 11 |
| Netherlands | 1 | 0 | 0 | 1 |
| Germany | 36 | 36 | 35 | 107 |
| United Kingdom | 8 | 10 | 9 | 27 |
| Italy | 9 | 9 | 7 | 25 |
| Sweden | 18 | 17 | 17 | 52 |
Ran from Nov 2008 to primary completion in Mar 2011, 27 months.
Results were first posted in Mar 2012, 1 year after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 27 months is above that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →